Quantifying between‐cohort and between‐sex genetic heterogeneity in major depressive disorder

Major depressive disorder (MDD) is clinically heterogeneous with prevalence rates twice as high in women as in men. There are many possible sources of heterogeneity in MDD most of which are not measured in a sufficiently comparable way across study samples. Here, we assess genetic heterogeneity base...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of medical genetics. Part B, Neuropsychiatric genetics Vol. 180; no. 6; pp. 439 - 447
Main Authors Trzaskowski, Maciej, Mehta, Divya, Peyrot, Wouter J., Hawkes, David, Davies, Daniel, Howard, David M., Kemper, Kathryn E., Sidorenko, Julia, Maier, Robert, Ripke, Stephan, Mattheisen, Manuel, Baune, Bernhard T., Grabe, Hans J., Heath, Andrew C., Jones, Lisa, Jones, Ian, Madden, Pamela A.F., McIntosh, Andrew M., Breen, Gerome, Lewis, Cathryn M., Børglum, Anders D., Sullivan, Patrick F., Martin, Nicholas G., Kendler, Kenneth S., Levinson, Douglas F., Wray, Naomi R.
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.09.2019
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Major depressive disorder (MDD) is clinically heterogeneous with prevalence rates twice as high in women as in men. There are many possible sources of heterogeneity in MDD most of which are not measured in a sufficiently comparable way across study samples. Here, we assess genetic heterogeneity based on two fundamental measures, between‐cohort and between‐sex heterogeneity. First, we used genome‐wide association study (GWAS) summary statistics to investigate between‐cohort genetic heterogeneity using the 29 research cohorts of the Psychiatric Genomics Consortium (PGC; N cases = 16,823, N controls = 25,632) and found that some of the cohort heterogeneity can be attributed to ascertainment differences (such as recruitment of cases from hospital vs. community sources). Second, we evaluated between‐sex genetic heterogeneity using GWAS summary statistics from the PGC, Kaiser Permanente GERA, UK Biobank, and the Danish iPSYCH studies but did not find convincing evidence for genetic differences between the sexes. We conclude that there is no evidence that the heterogeneity between MDD data sets and between sexes reflects genetic heterogeneity. Larger sample sizes with detailed phenotypic records and genomic data remain the key to overcome heterogeneity inherent in assessment of MDD.
Bibliography:Funding information
National Health & Medical Research Council, Award Numbers: 1087889, 1113400, 1078901
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Study design: MT, DM, NGM, DFS, NRW; Structured methodological review of PGC Cohorts: KSK, DFS, Analysis: MT, DM,DH, RM Analysis-PGC: SR, Analysis-UKB: DD,DH,KEK,JS, MT, AMc Analysis-Xchromosome: JS, MT. Analysis-iPSYCH: MM,ADB. PGC-MDD Principal Investigators: BTB,HJG, ACH, PAFM PGC-MDD Steering Committee: PFS, CML, GB, ADB, DFL, NRW. First draft of manuscript: MT, NRW. Final manuscript: all authors
Author Contributions
ISSN:1552-4841
1552-485X
1552-485X
DOI:10.1002/ajmg.b.32713